Prudent cost management in H1; FY20 goals reinstated
01/08/20 -"As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. ..."
Pages
50
Language
English
Published on
01/08/20
You may also be interested by these reports :
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...
30/05/26
With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex ...
28/05/26
Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent ...
27/05/26
Our target price has been revised upwards, driven by multiple Phase III readouts anticipated in 2026, expansion of the late-stage pipeline, and the ...